Cabozantinib
Common brands: Cabometyx, Opdivo, Cometriq, Katerzia, Norliqva
Top reporter: Exelixis, Inc.
Programmed Death Receptor-1 Blocking Antibody [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Corticosteroid [EPC]Dihydropyridine Calcium Channel Blocker [EPC]Calcium Channel Blocker [EPC]
46,986
Total Reports
32,516
Serious Reports
5,140
Death Reports
30
Reported Reactions
Death Report Ratio: High (10.94%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Cabozantinib.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | DIARRHOEA | 9,366 | |
| 2 | FATIGUE | 7,628 | |
| 3 | OFF LABEL USE | 6,782 | |
| 4 | NAUSEA | 4,944 | |
| 5 | DECREASED APPETITE | 4,579 | |
| 6 | MALIGNANT NEOPLASM PROGRESSION | 3,344 | |
| 7 | BLOOD PRESSURE INCREASED | 3,177 | |
| 8 | PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME | 3,079 | |
| 9 | WEIGHT DECREASED | 3,002 | |
| 10 | STOMATITIS | 2,875 | |
| 11 | DEATH | 2,781 | |
| 12 | CONSTIPATION | 2,352 | |
| 13 | VOMITING | 2,198 | |
| 14 | ASTHENIA | 2,124 | |
| 15 | BLISTER | 2,089 | |
| 16 | TASTE DISORDER | 1,981 | |
| 17 | HYPERTENSION | 1,861 | |
| 18 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 1,846 | |
| 19 | RASH | 1,805 | |
| 20 | PAIN IN EXTREMITY | 1,776 | |
| 21 | MALAISE | 1,775 | |
| 22 | DYSPHONIA | 1,391 | |
| 23 | ADVERSE DRUG REACTION | 1,350 | |
| 24 | DRY SKIN | 1,298 | |
| 25 | PAIN | 1,220 | |
| 26 | PRURITUS | 1,192 | |
| 27 | ORAL PAIN | 1,187 | |
| 28 | SKIN ULCER | 1,129 | |
| 29 | HEADACHE | 1,074 | |
| 30 | DIZZINESS | 1,033 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.